YHYvette Habraken

Yvette Habraken

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yvette Habraken has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Jacques Piette

    Laboratory of Virology and Immunology, GIGA-Signal Transduction, GIGA-B34, University of Liège, Liège, Belgium

    4 shared publications
  • Emmanuel Di Valentin

    GIGA-Viral Vector Platform, University of Liège, Liège, Belgium

    2 shared publications
  • Adeline Deward

    Laboratory of Virology and Immunology, GIGA-Signal Transduction, GIGA B34, University of Liège, avenue de l'Hôpital 1, 4000, Liège, Belgium.

    1 shared publication
  • Alain Colige

    Laboratory of Connective Tissues Biology, GIGA, Quartier Hôpital, University of Liège, Avenue Hippocrate 13, 4000 Liège, Belgium

    1 shared publication
  • Benoit Chabot

    Université de Sherbrooke, Faculté de médecine et des sciences de la santé Département de Microbiologie et d’Infectiologie, Sherbrooke, Canada

    1 shared publication
  • Benoit Hennuy

    GIGA Genomics Platform, University of Liège, avenue de l'Hôpital 1, 4000, Liège, Belgium.

    1 shared publication

Latest Publications

  • Melanoma antigen-D2: A nucleolar protein undergoing delocalization during cell cycle and after cellular stress

    by Céline Pirlot, Marc Thiry, Charlotte Trussart, Emmanuel Di Valentin, Jacques Piette, Yvette Habraken


  • Open Access

    Role of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosis

    by Maude Gabriel, Yves Delforge, Adeline Deward, Yvette Habraken, Benoit Hennuy, Jacques Piette, Roscoe Klinck, Benoit Chabot, Alain Colige, Charles Lambert

    Modification of splicing by chemotherapeutic drugs has usually been evaluated on a limited number of pre-mRNAs selected for their recognized or potential importance in cell proliferation or apoptosis. However, the pathways linking splicing alterations to the efficiency of cancer therapy remain unclear. Next-generation sequencing was used to analyse the transcriptome of breast carcinoma cells treated by cisplatin. Pharmacological inhibitors, RNA interference, cells deficient in specific signalling pathways, RT-PCR and FACS analysis were used to investigate how the anti-cancer drug cisplatin affected alternative splicing and the cell death pathway. We identified 717 splicing events affected by cisplatin, including 245 events involving cassette exons. Gene ontology analysis indicates that cell cycle, mRNA processing and pre-mRNA splicing were the main pathways affected. Importantly, the cisplatin–induced splicing alterations required class I PI3Ks P110β but not components such as ATM, ATR and p53 that are involved in the DNA damage response. The siRNA-mediated depletion of the splicing regulator SRSF4, but not SRSF6, expression abrogated many of the splicing alterations as well as cell death induced by cisplatin. Many of the splicing alterations induced by cisplatin are caused by SRSF4 and they contribute to apoptosis in a process requires class I PI3K.


  • Open Access

    Phosphorylation of p65(RelA) on Ser547 by ATM Represses NF-κB-Dependent Transcription of Specific Genes after Genotoxic Stress

    by Hélène Sabatel, Emmanuel Di Valentin, Geoffrey Gloire, Franck Dequiedt, Jacques Piette, Yvette Habraken

    The NF-κB pathway is involved in immune and inflammation responses, proliferation, differentiation and cell death or survival. It is activated by many external stimuli including genotoxic stress. DNA double-strand breaks activate NF-κB in an ATM-dependent manner. In this manuscript, a direct interaction between p65(RelA) and the N-terminal extremity of ATM is reported. We also report that only one of the five potential ATM-(S/T)Q target sites present in p65, namely Ser547, is specifically phosphorylated by ATM in vitro. A comparative transcriptomic analysis performed in HEK-293 cells expressing either wild-type HA-p65 or a non-phosphorylatable mutant HA-p65S547A identified several differentially transcribed genes after an etoposide treatment (e.g. IL8, A20, SELE). The transcription of these genes is increased in cells expressing the mutant. Substitution of Ser547 to alanine does not affect p65 binding abilities on the κB site of the IL8 promoter but reduces p65 interaction with HDAC1. Cells expressing p65S547A have a higher level of histone H3 acetylated on Lys9 at the IL8 promoter, which is in agreement with the higher gene induction observed. These results indicate that ATM regulates a sub-set of NF-κB dependent genes after a genotoxic stress by direct phosphorylation of p65.


  • NF-κB activation by double-strand breaks

    by Yvette Habraken, Jacques Piette


  • Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-κB activation by camptothecin and X-ray

    by Yvette Habraken, Olivier Jolois, Jacques Piette

    Camptothecin (CPT) and X-ray (XR) generate double-strand breaks (DSB) that can be processed by homologous or nonhomologous recombination. We studied the participation of proteins involved in recombination pathways and cell cycle control in the signal transduction between DNA damage and NF-κB. Cells harbouring mutated NBS, hMRE11, BRCA1 or MLH1 were analysed. NBS- and hMRE11-deficient cells present a classical kinetic of NF-κB induction after camptothecin treatment. When DSB are generated by XR, NBS-deficient cells exhibit a delayed and strongly reduced level of NF-κB induction, whereas the hMRE11 mutated cells do not induce NF-κB at all. This indicates an important role of the hMRE11/hRAD50/NBS complex in the signal transduction initiated by XR. In HCC1937 cells that express a truncated version of BRCA1, XR induces a very rapid and transient NF-κB activation, whereas CPT leads to a delayed activation suggesting that BRCA1 modulates the transduction pathways in different manners after these two stresses. Finally, we found that a proficient MMR pathway is essential to the NF-κB activation after both CPT and XR. These results indicate that DSB originating from XR or CPT do not induce NF-κB in a unique way. MMR participates in both cascades, whereas the hMRE11/hRAD50/NBS trimer is specifically involved in the response elicited by XR.